Finding inhibitors for PCSK9 using computational methods.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the key targets for atherosclerosis drug development as its binding with low-density lipoprotein receptor leads to atherosclerosis. The protein-ligand interaction helps to understand the actual mechanism for the pharmacological action....
Guardado en:
Autores principales: | Rida Zainab, Afshan Kaleem, Michał B Ponczek, Roheena Abdullah, Mehwish Iqtedar, Daniel C Hoessli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c99e97c78a2c47ea9969b0b623c9f424 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas CE, et al.
Publicado: (2020) -
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.
por: Rhogerry Deshycka, et al.
Publicado: (2021) -
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
por: Rhogerry Deshycka, et al.
Publicado: (2021) -
Current Evidence and Future Directions of PCSK9 Inhibition
por: Jiaqian Xu, et al.
Publicado: (2021) -
Effects of immunisation against PCSK9 in mice bearing melanoma
por: Amir Abbas Momtazi-Borojeni, et al.
Publicado: (2019)